Investment Thesis
Avalo Therapeutics is a pre-revenue pharmaceutical company burning $17.8M annually with only $59K in revenue, providing a cash runway of approximately 16-17 months at current burn rates. The company exhibits severe unprofitability (net margin of -33,271%) and cannot cover interest expenses from operations, indicating it will require substantial capital raises or immediate commercial success to survive. Despite a moderately strong balance sheet today, the fundamental financial trajectory is unsustainable.
Strengths
- Substantial liquidity cushion with $25.0M cash reserves and 7.66x current ratio reducing near-term insolvency risk
- Conservative leverage with 0.21x Debt/Equity ratio limiting financial distress impact
- Positive year-over-year improvement in diluted EPS (-0.98 vs prior -1.71, +72.1% improvement indicating operational progress)
Risks
- Critical cash burn of $17.8M annually with only 16-17 months of runway before capital requirement becomes acute
- Revenue collapse of 86.6% YoY with current revenue of $59K indicating no commercial traction or market validation
- Negative interest coverage (-32.9x) means company cannot service debt from operations, forcing reliance on asset liquidation or dilutive financing
- Binary pharmaceutical development risk: company will face extinction or massive dilution unless clinical programs achieve approval and revenue
Key Metrics to Watch
- Monthly cash burn trend and exact runway months remaining before forced capital raise
- Clinical program milestones and safety/efficacy data from ongoing trials
- Revenue and licensing deal announcements indicating commercialization path or partnerships
- Terms and dilution percentage of any capital raises or debt restructuring
Financial Metrics
Revenue
59.0K
Net Income
-19.6M
EPS (Diluted)
$-0.98
Free Cash Flow
-17.8M
Total Assets
99.9M
Cash
25.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-35,425.4%
Net Margin
-33,271.2%
ROE
-28.7%
ROA
-19.7%
FCF Margin
-30,145.8%
Balance Sheet & Liquidity
Current Ratio
7.66x
Quick Ratio
7.66x
Debt/Equity
0.21x
Debt/Assets
31.6%
Interest Coverage
-32.93x
Long-term Debt
14.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:29:01.746952 |
Data as of: 2026-03-31 |
Powered by Claude AI